

Classical Hodgkin lymphoma	
Pembrolizumab in children, adolescents, and young adults with low-risk classic Hodgkin lymphoma (cHL) and slow early response to front-line chemotherapy: updated results from the Phase 2 KEYNOTE-667 study. L. G. Roth.	Abstract #462, Oral session, Hodgkin lymphomas: clinical and epidemiological: potentially practice-changing trials in Hodgkin lymphoma
Pembrolizumab in children, adolescents, and young adults with high-risk classic Hodgkin lymphoma (cHL) with slow early response to front-line chemotherapy: updated results from the Phase 2 KEYNOTE-667 study. C. Mauz-Koerholz.	Abstract #3055, Poster session II, Hodgkin lymphomas: clinical and epidemiological
Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: KEYNOTE-B68 update. A. B. McDonald.	Abstract #3046, Poster session II, Hodgkin lymphomas: clinical and epidemiological
Diffuse large B-cell lymphoma	
WaveLINE-007: dose escalation and confirmation, and efficacy expansion trial of zilovetamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in patients with diffuse large B-cell lymphoma. M. Ozcan.	Abstract #578, Oral session, Aggressive lymphomas: pharmacologic therapies: new R-CHOP combinations for treatment naïve DLBCL
Updated results from the Phase 2 waveLINE-004 study of zilovetamab vedotin in relapsed or refractory diffuse large B-cell lymphoma. L. Norasetthada.	Abstract #1738, Poster session I, Aggressive lymphomas: pharmacologic therapies
Follicular lymphoma	
Nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma: results from the Phase 2 BELLWAVE-003 study. W. Jurczak.	Abstract #1634, Poster session I, Mantle cell, follicular, Waldenstrom's, and other indolent B-cell lymphomas: clinical and epidemiological
Mantle cell lymphoma	
Zilovetamab vedotin in combination with nemtabrutinib for patients with relapsed or refractory mantle cell lymphoma: cohort C of the open-label, Phase 2 waveLINE-006 study. E. Paszkiewicz-Kozik.	Abstract #3025, Poster session II, Mantle cell, follicular, Waldenstrom's, and other indolent B-cell lymphomas: clinical and epidemiological
Zilovetamab vedotin monotherapy for patients with relapsed or refractory mantle cell lymphoma: cohort A of the multicenter, open-label, Phase 2 waveLINE-006 study. I. Glimelius.	Abstract #4405, Poster session III, Mantle cell, follicular, Waldenstrom's, and other indolent B-cell lymphomas: clinical and epidemiological
Marginal zone lymphoma	
Nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory marginal zone lymphoma: results from the Phase 2 BELLWAVE-003 study. P. L. Zinzani.	Abstract #3016, Poster session II, Mantle cell, follicular, Waldenstrom's, and other indolent B-cell lymphomas: clinical and epidemiological